Medical/Pharmaceuticals
Terumo Medical Corporation Applauds ACC/AHA/SCAI Decision to Designate Radial Access Class 1, Level of Evidence A
SOMERSET, N.J., Jan. 11, 2022 /PRNewswire/ -- Terumo Medical Corporation (TMC) applauds the publication of updated guidelines from the American College of Cardiology (ACC), American Heart Association (AHA) and the Society for Cardiovascular Angiography and Interventions (SCAI) that give radial ac...
2022-01-12 03:40
2949
19Labs, QT Medical Launch Complete Telehealth Solutions With 12-Lead Resting ECG, Ultrasound, & More
SAN MATEO, Calif., Jan. 11, 2022 /PRNewswire/ -- Healthcare access is a huge challenge for millions of people worldwide. Physician shortages are common, and equipping some areas with proper diagnostic devices can be difficult and expensive. Some diagnostic tools can also be quite complex to opera...
2022-01-12 00:30
2437
Qilian International Holding Group Limited Releases 2022 Chairman Letter
JIUQUAN, China, Jan. 11, 2022 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), aChina-based pharmaceutical and chemical products manufacturer, today released a letter to shareholders from the Chairman of the Com...
2022-01-11 20:00
2505
Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct
SEATTLE and SAN FRANCISCO and SAN JOSE, Calif. and NANJING, China and SUZHOU, China andSHANGHAI, Jan. 10, 2022 /PRNewswire/ -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, IASO Biotherapeutics ("IASO Bio"), a clinical-stage ...
2022-01-11 05:30
3870
Trajan Group acquires Neoteryx LLC
MELBOURNE, Australia, Jan. 10, 2022 /PRNewswire/ -- Global analytical science and device company Trajan Group Holdings Limited (ASX: TRJ) (Trajan or the Company) has completed the acquisition of Neoteryx, LLC (Neoteryx), a global leader in blood microsampling devices based inTorrance, California,...
2022-01-11 00:00
3499
CARsgen Announces CT041 CAR T-cell Product Candidate Granted RMAT Designation by the FDA
SHANGHAI, Jan. 10, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, today announced thatthe United States Food and Drug Administration (FDA)...
2022-01-10 21:50
4244
SERIAL INNOVATOR, EITAN KONSTANTINO JOINS GENESIS MEDTECH AS CTO OF VASCULAR INTERVENTIONS FRANCHISE
SINGAPORE, Jan. 7, 2022 /PRNewswire/ -- Genesis MedTech Group (Genesis or Group) has appointed Dr.Eitan Konstantino (Eitan) as CTO of Vascular Interventions to propel Genesis' technology innovation within the neurovascular, cardiovascular and peripheral vascular spaces. His role will include dev...
2022-01-07 23:00
3839
KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE
SYDNEY, Jan. 7, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, DrJames Garner, will be speaking at the HC Wainwright BioConnect Conference, to be held virtually from10-13 January 2022. The co...
2022-01-07 21:00
5167
100% Recovery-GoldenBiotech Announces Topline Results from Unblinded COVID-19 Trial for Oral New Drug Antroquinonol in Hospitalized Mild, Moderate and Severe Patients
TAIPEI, Jan. 7, 2022 /PRNewswire/ -- Golden Biotechnology Corp.(TPEx:4132) ("GoldenBiotech", GBC), a leading Taiwanese biopharmaceutical company, announces that its Phase 2 COVID-19 trial for oral new drug Antroquinonol (HOCENA®) has achieved 100% recovery results of its primary outcome measure i...
2022-01-07 18:53
3140
Li Jian Quan, Chairman of WINNER MEDICAL Co., Ltd., Was Invited to "DIALOGUE PROGRAM" in CCTV-2 (China Central Television)
SHENZHEN, China, Jan. 7, 2022 /PRNewswire/ -- On the evening of January 1, Li Jian quan, chairman of Winner Medical, was a guest on "DIALOGUE PROGRAM" in CCTV-2 (China Central Television) as a representative of entrepreneurs. In the interview, he said that only by insisting on innovation can we b...
2022-01-07 17:47
2624
InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development
BEIJING, Jan. 7, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company executives will attend the upcoming investor conferences organized by Morgan Stanley and UBS to share company's latest development. Details are as follows: Morgan Stan...
2022-01-07 08:30
2873
LISCure Biosciences announces research collaboration with Mayo Clinic for rare liver diseases
SEOUL, South Korea, Jan. 6, 2022 /PRNewswire/ -- LISCure Biosciences Inc., a leading biotech focused on microbial-based therapeutics, announced that it has executed a research collaboration agreement with Mayo Clinic for new drug development for rare liver diseases. LISCure has been conducting j...
2022-01-06 22:00
2338
I-Mab Announces Senior Management Team Share Purchase Plan
SHANGHAI and GAITHERSBURG, MD., Jan. 6, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the senior management team of the Company, includin...
2022-01-06 21:00
4318
Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer's
MELBOURNE, Australia and SAN FRANCISCO, Jan. 6, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the United States Patent ...
2022-01-06 20:30
4245
AKESO'S CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) COMBINED WITH IVONESCIMAB (PD-1/VEGF BI-SPECIFIC ANTIBODY) COMBINED WITH OR WITHOUT CHEMOTHERAPY OBTAINED APPROVAL TO INITIATE A PHASE Ib/II CLINICAL TRIAL FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
HONG KONG, Jan. 6, 2022 /PRNewswire/ -- Today, Akeso, Inc. (09926.HK) announces that Cadonilimab (PD-1/CTLA-4 bi-specific antibody), the first-inclass novel immuno-oncology drug independently developed by the Company, combined with Ivonescimab (PD-1/VEGF bi-specific antibody), the novel immuno-o...
2022-01-06 19:00
2897
Nuance Pharma acquires Sino Health to further strengthen its commercial capabilities and expand pipelines
SHANGHAI, Jan. 6, 2022 /PRNewswire/ -- Nuance Pharma ("Nuance"or the "Company"), a specialty care focused biopharma with late late-stage clinical programs and existing commercial operations, today announced an agreement with Sino Health Pharmaceutical Limited ("Sino Health") , an affiliated compa...
2022-01-06 14:45
3878
Ascentage Pharma to Present at the J.P. Morgan 40th Annual Healthcare Conference
SUZHOU, China and ROCKVILLE, Md., Jan. 5, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its participation in and presentation at the 40th A...
2022-01-06 08:30
8053
Adlai Nortye Announces First Patient Dosed in Phase I Clinical Trial of the orally available, small-molecule PD-L1 inhibitor AN4005 for Advanced Tumors
NORTH BRUNSWICK, N.J. and HANGZHOU, China, Jan. 5, 2022 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye"), a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced that the first patient was dosed in the Phase I clinical trial in the U.S. to...
2022-01-06 01:00
2823
Metavention Completes U.S. Enrollment in Groundbreaking Feasibility Study to Treat Type 2 Diabetes
MINNEAPOLIS, Jan. 5, 2022 /PRNewswire/ -- Metavention, Inc. announces the completion of enrollment in the DeLIVER U.S. Study (NCT04285554), to evaluate the safety of sympathetic denervation of the liver using its new Integrated Radio Frequency (iRF) Denervation System. The purpose of the DeLIVER...
2022-01-05 22:00
2070
Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
MELBOURNE, Australia, Jan. 5, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced thatDavid Stamler, M.D., Chief Executive Of...
2022-01-05 20:45
4127
Week's Top Stories
Most Reposted
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 280 media titles]
2026-09-28 23:04
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 279 media titles]
2026-09-29 09:00
Allianz Partners unveils next-generation travel insurance platform to help partners navigate changing landscape
[Picked up by 269 media titles]
2026-09-28 07:30
Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 267 media titles]
2026-10-01 10:00
ViewSonic Launches VG1457 Dual-Screen Portable Monitor for Productivity Anywhere
[Picked up by 267 media titles]
2026-09-30 10:50
Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
22310
Luckin Coffee Celebrates 100 Stores in Singapore
2026-09-28 14:31
5925
